News Sentiment

ROIV sentiment intelligence

Roivant Sciences Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 31.43 Week of 19 Jun 2026
Weighted tone 60/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

73/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+4.6% over one week, +4.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

What Roivant Sciences (ROIV)'s $2.25 Billion Moderna Settlement and Immunology Wins Mean For Shareholders

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 73/100 classification
One-week reaction 4.6% Price confirming higher
Trend fit Trend active 4.9% over four weeks
Fair value 117.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 30
Neutral 22
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
MarketBeat 6
Insider Monkey 4
simplywall.st 4
Investing.com 4
Simply Wall Street 3
TradingKey 3
Moomoo 3

Event Lens

What the news is about

Classified themes
Earnings 21
Market update 19
Analyst action 11
Balance sheet 2
Deals and strategy 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Simply Wall Street Direct company coverage

What Roivant Sciences (ROIV)'s $2.25 Billion Moderna Settlement and Immunology Wins Mean For Shareholders

Roivant Sciences recently secured a $2.25 billion settlement with Moderna, resolving patent-infringement litigation. Concurrent with this, the company reported positive clinical results for IMVT-1402 in rheumatoid arthritis and received Breakthrough Therapy Designation for brepoc

Tone
Positive 72/100
Event
Earnings
Published
20 Jun 2026 16:40
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Roivant Sciences (ROIV) Stock Could Be 19.5% Undervalued After Moderna Settlement And Pipeline Progress

Roivant Sciences (ROIV) has garnered attention due to a $2.25 billion settlement with Moderna, positive IMVT-1402 rheumatoid arthritis data, and Breakthrough Therapy Designation for brepocitinib. The stock is currently trading at $31.43, which analysts estimate to be 19.5% underv

Tone
Positive 72/100
Event
Market update
Published
19 Jun 2026 13:09
Source
Simply Wall Street
TradingKey Direct company coverage

Roivant Sciences Ltd (ROIV) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Roivant Sciences Ltd (ROIV), highlighting its current risk score and market performance indicators. With a risk assessment score of 8.62, ROIV ranks 23 out of 157 in the Pharmaceuticals industry, indicating a slightly elevated risk prof

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 01:40
Source
TradingKey
The Globe and Mail Direct company coverage

Analysts’ Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (ENGN), Medtronic (MDT) and Roivant Sciences (ROIV)

This article summarizes recent analyst ratings for three healthcare stocks: enGene Holdings (ENGN), Medtronic (MDT), and Roivant Sciences (ROIV). Analysts have mixed opinions, with enGene Holdings receiving a "Hold" from Guggenheim and a "Moderate Buy" consensus, Medtronic gettin

Tone
Positive 71/100
Event
Analyst action
Published
18 Jun 2026 00:39
Source
The Globe and Mail
Insider Monkey Direct company coverage

Here is Why Roivant (ROIV) is One of the Best Growth Stocks Trading in Oversold Territory

Roivant Sciences Ltd. (NASDAQ: ROIV) is highlighted as a top growth stock in oversold territory after reporting strong financial results for FY2026, including $4.3 billion in cash and a significant settlement with Moderna. The company has a robust clinical pipeline with upcoming

Tone
Positive 72/100
Event
Earnings
Published
17 Jun 2026 09:46
Source
Insider Monkey
Insider Monkey Direct company coverage

12 Best Beaten Down Growth Stocks to Buy Right Now

This article identifies Roivant Sciences Ltd. (NASDAQ: ROIV) as a key "beaten down" growth stock, highlighting its strong financial position with $4.3 billion in cash and marketable securities and a significant $2.25 billion settlement with Moderna. The company also boasts a prom

Tone
Neutral 50/100
Event
Balance sheet
Published
15 Jun 2026 23:09
Source
Insider Monkey
DirectorsTalk Interviews Direct company coverage

Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a Potential 29.97% Upside in Biotech Innovation

Roivant Sciences Ltd. (ROIV) is analyzed as a promising biotech company with a potential 29.97% upside, driven by its innovative pipeline in autoimmune and cardiopulmonary diseases and strong analyst support. Despite financial challenges common to clinical-stage biotech firms, su

Tone
Positive 71/100
Event
Analyst action
Published
15 Jun 2026 10:20
Source
DirectorsTalk Interviews
MarketBeat Direct company coverage

Te Ahumairangi Investment Management Ltd Decreases Position in Roivant Sciences Ltd. $ROIV

Te Ahumairangi Investment Management Ltd reduced its stake in Roivant Sciences Ltd. by 33.6% in the fourth quarter of the previous year, selling 54,800 shares. Despite this, Wall Street analysts maintain a "Moderate Buy" consensus rating for Roivant Sciences with an average price

Tone
Neutral 50/100
Event
Earnings
Published
12 Jun 2026 09:40
Source
MarketBeat
MarketBeat Direct company coverage

Clearbridge Investments LLC Boosts Stock Holdings in Roivant Sciences Ltd. $ROIV

Clearbridge Investments LLC increased its stake in Roivant Sciences Ltd. by 7.7% in the fourth quarter, purchasing an additional 141,549 shares to bring its total holding to nearly 2 million shares valued at $42.8 million. Roivant Sciences has experienced significant institutiona

Tone
Positive 67/100
Event
Earnings
Published
10 Jun 2026 21:09
Source
MarketBeat
MarketBeat Direct company coverage

Bank of New York Mellon Corp Has $63 Million Stock Holdings in Roivant Sciences Ltd. $ROIV

Bank of New York Mellon Corp reduced its stake in Roivant Sciences Ltd. by 37.3% in the fourth quarter, yet still holds 2.9 million shares valued at approximately $63 million. Despite a recent earnings beat on EPS, revenue fell short of estimates, and the company continues to pos

Tone
Neutral 50/100
Event
Earnings
Published
10 Jun 2026 21:09
Source
MarketBeat
MarketBeat Direct company coverage

TD Asset Management Inc Purchases 235,176 Shares of Roivant Sciences Ltd. $ROIV

TD Asset Management Inc. significantly increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during Q4, purchasing an additional 235,176 shares, bringing its total to 551,376 shares valued at $12.0 million. Other major institutions like Vanguard and UBS also raised their hol

Tone
Positive 63/100
Event
Deals and strategy
Published
09 Jun 2026 21:39
Source
MarketBeat
Insider Monkey Direct company coverage

Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV)

Guggenheim maintained a Buy rating on Roivant Sciences Ltd. (ROIV) and increased its price target to $36, following the company's fiscal Q4 earnings and pipeline updates. Citi also raised its price target to $42 and reiterated a Buy rating, citing potential upside from second-hal

Tone
Positive 95/100
Event
Analyst action
Published
09 Jun 2026 18:10
Source
Insider Monkey
www.marketscreener.com Direct company coverage

Transcript : Roivant Sciences Ltd. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11

Roivant Sciences Ltd. presented at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The presentation, featuring analyst Corinne Jenkins, focused on insights and updates regarding the company. The full transcript of the event is available to subscribers.

Tone
Neutral 50/100
Event
Analyst action
Published
09 Jun 2026 12:25
Source
www.marketscreener.com
MarketBeat Direct company coverage

CenterBook Partners LP Purchases 364,390 Shares of Roivant Sciences Ltd. $ROIV

CenterBook Partners LP significantly increased its stake in Roivant Sciences Ltd. by 147.3% in the fourth quarter, buying 364,390 shares to bring its total holdings to 611,833 shares valued at approximately $13.3 million. Wall Street analysts maintain a "Moderate Buy" rating for

Tone
Neutral 50/100
Event
Earnings
Published
08 Jun 2026 21:39
Source
MarketBeat
MarketBeat Direct company coverage

Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of "Moderate Buy" by Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV) has received a "Moderate Buy" consensus rating from brokerages, with an average 1-year price target of $33.59. Various firms, including Citigroup and Guggenheim, recently raised their price targets for ROIV, despite a slight downgrade from Weis

Tone
Positive 67/100
Event
Analyst action
Published
06 Jun 2026 09:40
Source
MarketBeat
Intellectia AI Direct company coverage

ROIV Financials: Revenue Breakdown, Margins & Competitor Comparison

This article analyzes the financial performance of Roivant Sciences Ltd (ROIV), focusing on its revenue breakdown, profitability margins, and a comparison with competitors like INSM and INCY. ROIV exhibits a strong gross margin but negative operating and net margins, alongside a

Tone
Neutral 50/100
Event
Earnings
Published
02 Jun 2026 21:39
Source
Intellectia AI
DirectorsTalk Interviews Direct company coverage

Roivant Sciences Ltd. (ROIV) Stock Report: Analyzing The 30.18% Potential Upside

Roivant Sciences Ltd. (ROIV) is gaining investor attention with a market capitalization of $21.57 billion and a strong analyst consensus pointing to a 30.18% potential upside. The biopharmaceutical company, based in the UK, is focused on drug discovery and development, with lead

Tone
Positive 71/100
Event
Analyst action
Published
01 Jun 2026 10:18
Source
DirectorsTalk Interviews
Sahm Direct company coverage

Roivant Sciences (ROIV) Valuation After Strong IMVT-1402 Data And Late Stage Pipeline Momentum

Roivant Sciences (ROIV) is in focus after strong Phase 2b results for IMVT-1402 and recent earnings, leading to a significant year-to-date share price return. The company is considered 16.3% undervalued by some narratives, with a fair value target of $35.71, driven by a late-stag

Tone
Positive 70/100
Event
Earnings
Published
29 May 2026 18:09
Source
Sahm
FinancialContent Direct company coverage

Roivant Sciences Ltd. - Common Shares (NQ: ROIV)

This article provides financial news and press releases related to Roivant Sciences Ltd. (NQ: ROIV). It highlights recent stock performance, company announcements such as the unveiling of Priovant Therapeutics and ongoing registrational studies, and the announcement of 2021 Open

Tone
Positive 63/100
Event
Market update
Published
29 May 2026 15:10
Source
FinancialContent
Simply Wall Street Direct company coverage

Roivant Sciences (NasdaqGS:ROIV) Stock Forecast & Analyst Predictions

Roivant Sciences (NasdaqGS:ROIV) is forecast to grow earnings and revenue by 50% and 53.9% per annum respectively, although it is expected to remain unprofitable for the next three years. Analysts have frequently updated price targets and revenue estimates based on clinical trial

Tone
Positive 67/100
Event
Earnings
Published
27 May 2026 20:39
Source
Simply Wall Street
Moomoo Direct company coverage

J.P. Morgan Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $40

J.P. Morgan has reiterated its Buy rating on Roivant Sciences (ROIV.US) and increased its target price for the company's stock to $40. This move signals continued confidence from the financial institution regarding Roivant Sciences' future performance and valuation.

Tone
Positive 71/100
Event
Analyst action
Published
27 May 2026 15:10
Source
Moomoo